InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
20 déc. 2024 07h30 HE
|
InflaRx N.V.
JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...